Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 16/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | TEC | P42680 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22461454 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3BTKEGFR | |
| SCHEMBL24489983 | 0.92 | MAPT (0.43) | SLC6A2SLC6A4SLC6A3BTK | |
| SCHEMBL22460910 | 0.91 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3BTKESR1 | |
| SCHEMBL22461455 | 0.90 | BTK (0.44) | SLC6A2SLC6A4SLC6A3BTKEGFR | |
| SCHEMBL22461190 | 0.90 | BTK (0.44) | SLC6A2SLC6A4SLC6A3BTKEGFR | |
| SCHEMBL24489998 | 0.89 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3BTKEGFR | |
| SCHEMBL22461555 | 0.89 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3BTKEGFR | |
| SCHEMBL24489980 | 0.84 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3BTKEGFR | |
| SCHEMBL24490210 | 0.83 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3ESR1ESR2 | |
| SCHEMBL22461281 | 0.83 | KIF11 (0.45) | SLC6A2SLC6A4SLC6A3ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086194-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | Suvalent Therapeutics, Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | CIT THERAPEUTICS LLC | 2022-06-09 | — | — | US | disclosed |
| WO-2020191151-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | ONCOVALENT THERAPEUTICS INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | SUMO1, SUMO2, SUMO3 | SLC6A2 4575/4885SLC6A4 4468/4885SLC6A3 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.